iPSC-based therapy dilemmas explored: overcoming hurdles for future success
Notice bibliographique
Résumé
As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of the industry’s iPSC development efforts. Despite these noteworthy strides, there are still many existing dilemmas to address for sustained progress and commercial viability. In this article, four esteemed industry experts delve into the critical aspects of reshaping the future landscape of iPSC-based therapies, exploring key areas such as material access and readiness, operational intricacies, technological innovations, and standardization.Melissa Carpenter has worked on the development of cell therapies using human adult and embryonic stem cells for the last 20 years, in academia and industry, in the US and Canada. She has been involved with human embryonic stem cell (hESC) research since the field was established. Her work involves discovery research and the translation of this research into therapeutics, including developing strategies for preclinical development and navigating the regulatory issues surrounding stem cell therapies. She has held leadership positions at three of the major stem cell companies: CytoTherapeutics, Inc (StemCells, Inc.), Geron, Corp., and Novocell, Inc (Viacyte, Inc). Currently, Carpenter is President of Carpenter Group Consulting and works with early stage companies, academic groups and investors to translate discovery based research into stem cell therapies. She is credited with numerous publications and patents in the stem cell field.Lise Munsie earned her PhD at McMaster University, Hamilton, ON, Canada, focusing on drug discovery in neurodegenerative diseases. Following this, she completed a post-doctoral research fellowship at the Centre for Applied Neurogenetics at the University of British Columbia, Vancouver, BC, Canada, where she focused on the genetic causes of Parkinson’s Disease. Lise joined CCRM, Toronto, ON, Canada, in 2015 and is currently the Vice President of the iPSC Technology Platform for CCRM, and its affiliate, OmniaBio Inc. Lise manages iPSC reprogramming, gene editing, cell banking, scale-up, and differentiation projects. Lise’s team critical focus is enabling these technologies to be manufactured to produce clinically relevant products.Kim Raineri is the Chief Technology Officer for Aspen Neuroscience, Inc., San Diego, CA, USA. He is responsible for the manufacturing, process and analytical development, technology development, and delivery device functions of a leading autologous iPSC derived cell therapy company targeting CNS diseases. Prior to this position he was the Chief Manufacturing and Technology Officer for AVROBIO, Inc., responsible for the CMC, process and analytical development, supply chain, and external manufacturing functions of a leading gene therapy company targeting Lysosomal Storage Disorders through ex vivo lentiviral gene therapy. Prior to this role, he held various positions of responsibility in cell and gene therapy CDMO as Vice President of Operations for Nikon CeLL innovation, Business Director for Lonza Bioscience Singapore Pte Ltd., and Director of Operations for Lonza Walkersville. Raineri has a MBA from Kennesaw State University, Kennesaw, GA, USA, and BSc from the University of Miami, Coral Gables, FL, USA.Bruno Marques is Vice President of Process and Product Development at Century Therapeutics, Philadelphia, PA, USA, with a focus on allogeneic, iPSC-derived therapies for cancer and autoimmune diseases. He is a chemical engineer by training, with a PhD from Carnegie Mellon University, Pittsburgh, PA, USA, and a BS from the Illinois Institute of Technology, Chicago, IL, USA.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».